First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial - FAST

Proctor Foundation University of California0 个研究点目标入组 130 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1) Historical non-infectious intermediate, anterior and intermediate, posterior or panuveitis in at least one eye
•2) Active inflammation within the last 180 days, defined by the presence of any of the following (in at least one eye) according to SUN criteria:
•a) >= 2+ anterior chamber cells
•b) >= 2+ vitreous haze
•c) active retinal or choroidal lesions
•3) Active inflammation at enrollment, defined by the presence of any of the following (in at least one eye) according to SUN criteria:
•a) >=1+ anterior chamber cells and/or
•b) >=1+ vitreous haze and/or
•c) active retinal/choroidal lesions

•1) Any infectious cause of uveitis
•2) Prior immunosuppressive therapy other than corticosteroids in the past 12 months
•3) Prior intolerability or safety issues with methotrexate or mycophenolate mofetil
•4) Prior failure to control ocular or other inflammation using methotrexate or mycophenolate mofetil
•5) Prior biologic therapy at any time
•6) Media opacity (such as cataract and/or corneal scar) and/or extensive posterior synechiae such that examination of the posterior segment is not possible in both eyes
•7) Chronic hypotony (IOP < 5 mm Hg for > 3 months) in both eyes
•8) Periocular or intravitreal corticosteroid injection in the past 4 weeks
•9) Fluocinolone acetonide implant in either eye in < 3 years
•10) Intraocular surgery in < 30 days, or planning on getting surgery within the next 6 months
•11) Best spectacle-corrected visual acuity (BSCVA) of hand motions or worse in better eye
•< 16 years of age at enrollment

发起方

Proctor Foundation University of California